Introduction
Vitamin D supplementation is widely recommended and used in the prevention and treatment of osteoporosis. (1) However, meta-analyses have failed to demonstrate effects of these supplements used alone on bone mineral density (BMD) or fracture. (2) (3) (4) (5) In contrast, vitamin D treatment of patients with severe vitamin D deficiency resulting in osteomalacia, produces increases in absolute BMD of as much as 50% in 12 months. (6) This suggests that trials to-date have not been carried out in sufficiently D-deficient individuals. This possibility is supported by the finding that when BMD trials are categorized according to baseline 25-hydroxyvitamin D (25OHD) concentrations above or below 50 nmol/L, a significant treatment effect is found in studies below this threshold, but not in the equal number of studies above this level. (2) That division of studies at 50 nmol/L in that analysis was determined a priori, but a post hoc examination of the trial results in that meta-analysis indicated that benefit was only found in trials with baseline 25OHD <40 nmol/L. (2) The possibility that baseline 25OHD influences treatment response to vitamin D has recently been assessed in detail in the bone density sub-study of the Vitamin D Assessment (ViDA) Study. (7) In that Auckland, New Zealand study, 452 older adults with a mean baseline 25OHD concentration of 56 nmol/L were randomized to vitamin D or placebo for 2 years. In the whole cohort, there was no significant treatment effect in the lumbar spine or total body, but BMD loss at both hip sites was attenuated by ~0.5% over 2 years. There was a significant interaction between baseline 25OHD and treatment effect. With baseline 25OHD ≤30 nmol/L (n=46), there were between-groups BMD changes at the spine and femoral sites of ~2%, significant in the spine and femoral neck. When baseline 25OHD was >30 nmol/L, This article is protected by copyright. All rights reserved differences were ~0.5% and significant only at the total hip. When the cohort was divided at 40 or 50 nmol/L, the contrast in treatment effects above and below the thresholds was less marked, with between-groups differences for change in BMD being very similar at >30, >40 or >50 nmol/L.
Macdonald et al have carried out a similar trial over one year in 305 postmenopausal women in Aberdeen. (8) Like the ViDA-BMD study, all participants were enrolled at the end of winter and 25OHD was measured using liquid chromatography-tandem mass spectrometry. In the Aberdeen study, baseline 25OHD concentrations were lower, at 34 (SD 15) nmol/L. Mean BMD loss at the hip was reduced by vitamin D 1000 IU/day only. There was no significant treatment effect of either dose at the lumbar spine. No analysis of the effect of baseline 25OHD on treatment response was carried out.
The present report presents a re-analysis of the Aberdeen trial to determine whether the 30 nmol/L threshold of baseline 25OHD for a vitamin D treatment effect on BMD found in the ViDA-BMD study, can be confirmed in this independent trial cohort which shared important design elements. In other words, we are using the Aberdeen trial as a validation cohort for the results found in the ViDA study. This article is protected by copyright. All rights reserved
Methods
The details of the Aberdeen study have already been described. (8) In brief, this was a 1-year, double-blind, placebo-controlled trial to determine the effects of daily oral vitamin D3 in doses of 400 IU or 1000 IU, compared with placebo, on BMD in 305 non-smoking women from the northeast of Scotland, aged 60 -70 years. (8) All participants started the trial between January and March 2009. BMD was measured using a Lunar iDXA, (GE Medical, Madison, WI), and 25OHD by tandem mass spectrometry using the US National Institute of Standards and Technology standard, (9) in a laboratory which takes part in the DEQAS quality-control scheme for vitamin D and has full certification via this scheme. Inter-assay coefficients of variation were <10% for both 25OHD2 and 25OHD3, and the sum of these analytes is reported here. The 25OHD metabolite, 24,25-dihydroxyvitamin D was also measured by tandem mass spectrometry using a prior de-lipidation procedure to maximise recovery. (10) Overnight fasted blood samples collected at each visit were stored at -80°C, and each participant's complete set batched together before analysis. Details of analysis techniques have already been reported. (8) Since this was a reanalysis of an existing study no power analyses were performed.
The primary comparison of the effects of treatment on BMD in those with baseline 25OHD levels above and below 30 nmol/L was pre-specified. Time-course data were analyzed using a mixed models approach to repeated measures with an unstructured covariance matrix. Significant main and or interaction effects were further explored using the method of Tukey.
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This article is protected by copyright. All rights reserved nmol/L, there was no loss of spine BMD in the placebo group and no significant treatment effect at either site. This article is protected by copyright. All rights reserved While this study set out to validate the 30 nmol/L threshold for 25OHD identified in the ViDA study, exploratory analyses of other thresholds have also been undertaken.
Dividing the cohort at 25 nmol/L tended to produce even more marked contrasts: a >2% treatment effect at the spine (1000 IU/day compared with placebo, P = 0.002) and ~1% at the hip, in those with 25OHD ≤ 25 nmol/L, compared with no treatment effects in those starting above this level (P 0.14 -0.44). The distribution of 25OHD concentrations in this cohort made it difficult to rigorously assess 50 nmol/L and 75 nmol/L thresholds, since numbers per treatment group above these levels were 9-17 and 0-3, respectively. No treatment effects were seen at the hip above these higher thresholds. In the spine in subjects >50 nmol/L, the 400 IU vitamin D dose tended to reduce BMD and the 1000 IU dose to increase it; with only 9 in each treatment group, these findings are not reliable.
An exploratory analysis was conducted to determine whether the baseline ratio of 25OHD: 24,25-dihydroxyvitamin D predicted the BMD response to vitamin D supplementation. Grouping participants by quartiles of this ratio showed no interaction with BMD response in either the spine (P = 0.51) or hip (P = 0.40). This article is protected by copyright. All rights reserved
Discussion
The present analysis confirms that a 25OHD concentration of 30 nmol/L represents a threshold for the beneficial effects of vitamin D supplements on BMD. Supplementation of individuals below this level results in gains in BMD, but above this level there is no significant change. This finding relates to late winter levels of 25OHD using an appropriately calibrated assay in a fair-skinned population, and should be applied to other contexts with these caveats in mind. The mechanism of this effect is likely to be the correction of secondary hyperparathyroidism, since the present analyses also show differential changes in PTH according to baseline 25OHD status. This agrees with previous studies suggesting a threshold for PTH suppression by vitamin D in the region of 40 -50 nmol/L. (11, 12) However, this does not prove that the change in PTH causes the changes in BMD. In individuals with the lowest 25OHD concentrations, healing of osteomalacia may also be a mechanism contributing to the increase in BMD.
Interestingly, there was no evidence of changes in markers of bone turnover in the D-deficient participants in the present study, nor of suppression of markers following vitamin D supplementation. We have previously observed reductions in PINP in individuals with 25OHD < 30 nmol/L given a 500,000 IU bolus of vitamin D, (11) but daily dosing in deficient individuals seems to produce no change in alkaline phosphatase (13) nor in osteocalcin, pyridinoline or deoxypyridinoline, (14) the latter two markers actually appearing to rise in some groups. These mixed results might reflect the complexity of vitamin D action on bone: the correction of secondary hyperparathyroidism tends to reduce turnover, but direct effects of vitamin D on bone cells can have the opposite effect, as seen is osteomalacia treatment where marker This article is protected by copyright. All rights reserved levels rise substantially. BMD changes following vitamin D supplementation might also result from changes in bone mineralization occurring independently of bone turnover. There is evidence that 1,25-dihydroxyvitamin D directly regulates pyrophosphate concentrations in bone thus influencing mineralization, which might mediate such an effect. (15) Several factors are likely to have contributed to the congruence between the ViDA-BMD and the Aberdeen results. Both studies recruited participants in late winter or early spring, when 25OHD levels are at their nadir. In most other trials of vitamin D supplementation, participants have been recruited over the whole year so changing seasons will have added to variability of 25OHD concentrations by 20 nmol/L or more. (16, 17) Thus, an individual whose 25OHD is 30 nmol/L at its nadir, may be 50 nmol/L or more following the summer peak, as seen in the placebo group in Figure 1 .
In trials with this extent of variation in baseline 25OHD, identifying a threshold for effect is much more difficult.
A second factor influencing the apparent 25OHD threshold for the effect of vitamin D supplements is the calibration of the 25OHD assay. The fact that both the ViDA and Aberdeen studies used state-of-the-art tandem mass spectrometry assays is likely to have contributed to the congruence of the findings between the studies, since variations in calibration between different 25OHD assays of up to 80% have been reported in the past. (18) It is of interest to note that the Fraser laboratory, which carried out the present 25OHD measurements, has now added a delipidation step to 
Authors' Roles
HMM, IRR and GDG had full access to the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. HMM was involved in the original study design and study management, and the writing of the manuscript. IRR proposed the present re-analysis and wrote first draft of the manuscript. GDG undertook the analyses and produced the figures. WDF and JCT offered analysis and interpretation of biochemical measurements. ADW was responsible for the day-to-day running of the original study. All authors critically appraised the manuscript. This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved 
21
This article is protected by copyright. All rights reserved 
24
25
